Latest News about NBIX
Recent news which mentions NBIX
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
August 29, 2024
From Benzinga
From Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
August 28, 2024
From Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
From Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
August 28, 2024
From Benzinga
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
From Benzinga
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
From Benzinga
From InvestorPlace
Tickers
NBIX
From InvestorPlace
3 Red-Hot Biotech Rockets Blasting Off in 2024
April 24, 2024
From InvestorPlace
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
From Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
From Benzinga
From InvestorPlace
From Benzinga
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
February 08, 2024
Tickers
NBIX
From Benzinga
Earnings Scheduled For February 7, 2024
February 07, 2024
From Benzinga
From InvestorPlace
3 Stocks at the Forefront of Medical Innovation
December 25, 2023
From InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
From InvestorPlace
Analyst Expectations for Neurocrine Biosciences's Future
December 07, 2023
Tickers
NBIX
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.